Head-to-head evidence
amycretin vs dulaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
amycretin
Developed by Novo Nordisk
NCT06542874 · Phase 2 · completed
This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2028 · NCT07400107 (registry estimate)
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · dulaglutide's landscape